Bristol's Breyanzi, Off To A ‘Good Start,’ Shows Efficacy In Earlier Lymphoma Setting

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The CAR-T therapy met the primary endpoint of improvement in event-free survival in a Phase III trial evaluating Breyanzi as a second-line alternative to stem cell transplant in large B-cell lymphoma.

Bullseye
Bristol's Breyanzi succeeded in a Phase III trial in an earlier setting • Source: Alamy

Bristol Myers Squibb Company's CAR-T therapy Breyanzi (lisocabtagene maraleucel), approved in the US earlier this year for the third-line treatment of certain relapsed/refractory large B-cell lymphoma (LBCL), may now have a near-term path to the second-line setting. The company announced on 10 June that a Phase III trial testing Breyanzi as a second-line treatment compared to the standard of care – salvage therapy followed by high-dose chemotherapy and hematopoietic stem cell transplant – met the primary endpoint of improvement in event-free survival.

Breyanzi was the third CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy to reach the market for certain lymphoma indications, more...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D